BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 25597638)

  • 1. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
    Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
    J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.
    Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y
    Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionalized magnetic dextran-spermine nanocarriers for targeted delivery of doxorubicin to breast cancer cells.
    Tarvirdipour S; Vasheghani-Farahani E; Soleimani M; Bardania H
    Int J Pharm; 2016 Mar; 501(1-2):331-41. PubMed ID: 26875475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice.
    Mondal L; Mukherjee B; Das K; Bhattacharya S; Dutta D; Chakraborty S; Pal MM; Gaonkar RH; Debnath MC
    Int J Nanomedicine; 2019; 14():8073-8094. PubMed ID: 31632019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
    Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
    Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
    J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
    Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
    J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
    Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
    J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Na
    Araste F; Abnous K; Hashemi M; Dehshahri A; Detampel P; Alibolandi M; Ramezani M
    Eur J Pharm Sci; 2020 Feb; 143():105207. PubMed ID: 31870814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesoporous silica coated gold nanorods loaded doxorubicin for combined chemo-photothermal therapy.
    Monem AS; Elbialy N; Mohamed N
    Int J Pharm; 2014 Aug; 470(1-2):1-7. PubMed ID: 24792973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.
    Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J
    Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer.
    Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G
    Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy.
    Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y
    Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
    Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
    Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
    Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
    Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
    Naruphontjirakul P; Viravaidya-Pasuwat K
    Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab.
    Yousefpour P; Atyabi F; Vasheghani-Farahani E; Movahedi AA; Dinarvand R
    Int J Nanomedicine; 2011; 6():1977-90. PubMed ID: 21976974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.